Journal Guide
European Heart Journal Impact Factor 35.6: Publishing Guide
ESC's flagship cardiovascular journal: where European scope meets global impact in cardiovascular innovation
35.6
Impact Factor (2024)
~10%
Acceptance Rate
~20 days
Time to First Decision
What European Heart Journal Publishes
European Heart Journal is the European Society of Cardiology's flagship publication and one of the world's leading cardiovascular journals. It publishes cardiovascular research with a European perspective but global relevance, particularly favoring large registry studies, landmark trials, and work that could influence ESC guidelines.
- Large-scale cardiovascular clinical trials and registries
- Epidemiological studies with practice-changing implications
- Cardiovascular interventions and device studies
- Heart failure, coronary disease, and arrhythmia management
- Cardiovascular imaging and diagnostic innovations
- Preventive cardiology and population health research
Editor Insight
“European Heart Journal succeeds because we understand that cardiovascular medicine is both local and global. European healthcare systems and populations provide unique insights, but the findings must matter for cardiovascular care worldwide. We want research that will be discussed in catheterization labs and heart failure clinics from Stockholm to Singapore.”
What European Heart Journal Editors Look For
European scope with global relevance
Research from European investigators or with European populations gets favorable consideration, but findings must have global applicability. ESC wants to lead international cardiovascular medicine, not just European practice.
Large registry studies and real-world evidence
European Heart Journal loves big numbers. Registry studies with thousands of patients, population-based cohorts, and real-world effectiveness studies perform exceptionally well here.
Practice-changing cardiovascular research
Studies that will influence ESC guidelines, change how cardiologists practice, or affect cardiovascular outcomes at population scale. Academic exercises without practice impact face an uphill battle.
Methodological rigor in cardiovascular outcomes
Hard endpoints: death, MI, stroke, hospitalizations. Surrogate endpoints face skepticism unless the pathway to clinical benefit is crystal clear.
Innovation in cardiovascular care delivery
New technologies, care pathways, or interventions that could transform how cardiovascular medicine is practiced. Innovation with evidence, not just promise.
Integration across cardiovascular subspecialties
Research that connects different areas of cardiology - interventional, electrophysiology, heart failure, imaging - often resonates strongly with editors.
Why Papers Get Rejected
These patterns appear repeatedly in manuscripts that don't make it past European Heart Journal's editorial review:
Small single-center studies without broader relevance
European Heart Journal wants research that matters at scale. Single-center studies with <500 patients face tough odds unless they're investigating rare conditions or novel mechanisms.
Ignoring European context and ESC guideline relevance
If your work has implications for ESC guidelines or European practice patterns, make this explicit. Editors want research that advances European cardiovascular medicine leadership.
Weak statistical power for cardiovascular endpoints
Cardiovascular trials need adequate power for clinical endpoints. Studies powered for surrogate endpoints but claiming clinical benefit get rejected for overstating conclusions.
Poor integration with existing cardiovascular evidence
Cardiovascular medicine has extensive evidence bases. Failing to contextualize your findings within existing literature suggests you don't understand the field deeply enough.
Overly specialized findings without general cardiology relevance
Ultra-specialized research in narrow cardiovascular niches belongs in subspecialty journals. European Heart Journal serves general cardiology with broad subspecialty appeal.
Inadequate attention to cardiovascular risk factors
European cardiology emphasizes prevention and risk factor management. Studies that ignore these dimensions miss opportunities to demonstrate broader cardiovascular relevance.
Does your manuscript avoid these patterns?
The quick diagnostic reads your full manuscript against European Heart Journal's criteria and flags the specific issues most likely to cause rejection.
Insider Tips from European Heart Journal Authors
ESC registry data is a golden pathway
If you have access to ESC registry data or can contribute to ongoing ESC registries, this creates natural alignment with editorial priorities. Registry-based studies perform exceptionally well.
The ESC guideline connection is real
European Heart Journal papers often become the evidence base for ESC guidelines. If your research addresses guideline gaps or controversies, emphasize this potential impact.
Big numbers matter more than elegant mechanisms
A 50,000-patient registry study with modest effect sizes often trumps a 200-patient mechanistic study with dramatic findings. Scale and clinical relevance win over biological insights.
European authorship helps but isn't essential
Having European co-authors or European study sites strengthens submissions, but excellent research from other continents gets published if it has global relevance.
Cardiovascular imaging papers do particularly well
European Heart Journal has a strong tradition in cardiovascular imaging research. Novel imaging techniques, outcome predictions from imaging, or imaging-guided therapy studies get favorable review.
The rapid publication track exists for urgent findings
For time-sensitive cardiovascular research - safety signals, practice-changing results, pandemic-related findings - European Heart Journal offers expedited review and publication.
Population health and prevention are editorial priorities
Studies on cardiovascular disease prevention, population screening, or health system interventions align with ESC's public health mission and get serious consideration.
Heart failure research has particular prominence
Given the aging European population and heart failure epidemic, well-designed heart failure studies get prioritized. This includes device studies, drug trials, and care delivery research.
The European Heart Journal Submission Process
Direct submission
Editorial assignment within daysSubmit complete manuscript emphasizing cardiovascular practice relevance and European/global applicability. Include clear power calculations and endpoint justifications.
Editorial screening
1 weekESC editors assess cardiovascular significance, methodological adequacy, and fit with journal scope. About 70% desk rejection rate.
Expert cardiovascular review
2-3 weeks2-3 reviewers including practicing cardiologists and cardiovascular researchers. Focus on clinical relevance and methodological rigor.
Statistical review
Concurrent with peer reviewDedicated biostatistical review for clinical studies. Particular attention to cardiovascular endpoint definitions and analysis approaches.
Final decision
~20 days totalAccept, reject, or revise based on cardiovascular practice impact and methodological soundness. Fast turnaround prioritized.
European Heart Journal by the Numbers
| 2024 Impact Factor(Clarivate JCR; highest in cardiovascular medicine) | 39.3 |
| Submissions per year | ~3,000 |
| Acceptance rate | ~10% |
| Desk rejection rate | ~70% |
| Time to first decision | ~20 days |
| ESC membership | 100,000+ cardiologists |
| Geographic reach | European focus, global impact |
| Weekly publication | 48 issues/year |
Before you submit
European Heart Journal accepts a small fraction of submissions. Make your attempt count.
The pre-submission diagnostic runs a live literature search, scores your manuscript section by section, and gives you a prioritized fix list calibrated to European Heart Journal. ~30 minutes.
Article Types
Clinical Research
4,000 wordsOriginal cardiovascular clinical studies
Basic Science
4,000 wordsCardiovascular basic research with clinical relevance
Rapid Communication
2,000 wordsUrgent cardiovascular findings requiring immediate publication
Review
6,000 wordsIn-depth cardiovascular reviews (often invited)
Landmark European Heart Journal Papers
Papers that defined fields and changed science:
- ESC/EAS Guidelines for management of dyslipidaemias (2019, practice-defining)
- EuroHeart Survey registry studies (2000s-2010s, real-world evidence)
- SYNTAX trial: PCI vs CABG for complex coronary disease (2009, practice-changing)
- European Heart Rhythm Association studies on atrial fibrillation (2010s)
- COVID-19 cardiovascular complications registries (2020-2021)
Preparing a European Heart Journal Submission?
Get pre-submission feedback from reviewers who've published in European Heart Journal and know exactly what editors look for.
Run Free Readiness ScanNeed expert depth? Human review from $1,000
Primary Fields
Ready to submit to European Heart Journal?
A desk rejection costs months. Get expert feedback before you submit, from scientists who know exactly what European Heart Journal editors look for.
Avoid Desk Rejection
Get expert pre-submission review before you submit to European Heart Journal. 3-7 day turnaround.
Manuscript Rejected?
Expert revision help to strengthen your manuscript and resubmit with confidence.
Reviewer Response Help
Get expert guidance crafting your response to European Heart Journal reviewers.
Need field-expert depth? Human review from $1,000